X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-11-07 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $20.22 | -200,000 | 1,504,959 | -12% | -$4,044,000 | |||||
| D | 2025-11-06 | BBIO | Bridgebio Pharma, Inc. | Daniels Ronald J | Dir | S - Sale+OE | $63.72 | -61,031 | 16,991 | -78% | -$3,888,999 | |||||
2025-11-06 | IONS | Ionis Pharmaceuticals Inc | Birchler Brian | EVP, Corp, Development Ops | S - Sale | $76.17 | -8,000 | 48,826 | -14% | -$609,379 | ||||||
| DM | 2025-11-05 | IONS | Ionis Pharmaceuticals Inc | Geary Richard S | EVP, Chief Development Officer | S - Sale+OE | $75.69 | -34,639 | 59,657 | -37% | -$2,621,816 | |||||
| AD | 2025-11-03 | IONS | Ionis Pharmaceuticals Inc | Geary Richard S | EVP, Chief Development Officer | S - Sale+OE | $75.05 | -1,680 | 59,657 | -3% | -$126,091 | |||||
| D | 2025-11-05 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $75.36 | -20,000 | 5,287 | -79% | -$1,507,122 | |||||
2025-11-06 | EVOK | Evoke Pharma Inc | Klein Roger M. | 10% | S - Sale | $10.65 | -9,000 | 154,000 | -6% | -$95,885 | ||||||
2025-11-06 | ZOMDF | Zomedica Corp. | Klass Russell Kevin | SVP, Sales | P - Purchase | $0.08 | +253,007 | 5,509,101 | +5% | +$20,241 | ||||||
2025-11-05 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale | $27.00 | -71,381 | 176,549 | -29% | -$1,927,287 | ||||||
| DM | 2025-11-06 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $448.41 | -8,000 | 644,489 | -1% | -$3,587,316 | |||||
2025-11-06 | COLL | Collegium Pharmaceutical, Inc | Tupper Colleen | EVP, CFO | S - Sale | $40.53 | -30,000 | 126,667 | -19% | -$1,215,753 | ||||||
2025-11-07 | ARVN | Arvinas, Inc. | Loomis David K | Chief Accounting Officer | S - Sale | $9.89 | -230 | 31,697 | -1% | -$2,275 | ||||||
| D | 2025-11-05 | MDGL | Madrigal Pharmaceuticals, Inc. | Bate Kenneth | Dir | S - Sale+OE | $484.31 | -16,575 | 2,627 | -86% | -$8,027,354 | |||||
| D | 2025-11-05 | GALT | Galectin Therapeutics Inc | Lewis Joel | Pres, CEO | S - Sale+OE | $6.00 | -200 | 834,592 | 0% | -$1,200 | |||||
| D | 2025-11-05 | GALT | Galectin Therapeutics Inc | Callicutt Jack W | CFO | S - Sale+OE | $6.00 | -600 | 7,614 | -7% | -$3,600 | |||||
2025-11-05 | OCUL | Ocular Therapeutix, Inc | Saroj Namrata | Chief Business Officer | S - Sale | $10.74 | -25,865 | 174,135 | -13% | -$277,790 | ||||||
| M | 2025-11-04 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $1.22 | -155,885 | 3,787,474 | -4% | -$189,830 | |||||
| M | 2025-11-04 | HOWL | Werewolf Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale | $1.22 | -242,890 | 5,904,720 | -4% | -$295,781 | |||||
| M | 2025-11-04 | HOWL | Werewolf Therapeutics, Inc. | Gadicke Ansbert | 10% | S - Sale | $1.22 | -242,890 | 5,904,720 | -4% | -$295,781 | |||||
2025-11-04 | ANTX | An2 Therapeutics, Inc. | Eizen Joshua M | See Remarks | S - Sale | $1.14 | -2,819 | 177,353 | -2% | -$3,214 | ||||||
2025-11-04 | ANTX | An2 Therapeutics, Inc. | Prior Stephen David | Chief Strategy Officer | S - Sale | $1.14 | -765 | 65,548 | -1% | -$872 | ||||||
| DM | 2025-11-04 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $42.16 | -7,040 | 79,240 | -8% | -$296,778 | |||||
| D | 2025-11-04 | QURE | Uniqure N.V. | Kaye Jack | Dir | S - Sale+OE | $30.34 | -38,810 | 20,439 | -66% | -$1,177,517 | |||||
| D | 2025-11-05 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $4.24 | -3,398 | 0 | -100% | -$14,408 | |||||
| DM | 2025-11-04 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $436.05 | -8,000 | 644,489 | -1% | -$3,488,423 | |||||
| D | 2025-11-04 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, Chief Accounting Officer | S - Sale+OE | $36.00 | -67,115 | 48,545 | -58% | -$2,416,140 | |||||
2025-11-05 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $951.56 | -40,432 | 93,711,978 | 0% | -$38,473,442 | ||||||
2025-11-05 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $933.26 | -179,042 | 93,752,410 | 0% | -$167,092,104 | ||||||
2025-11-03 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $9.74 | -3,299 | 438,818 | -1% | -$32,146 | ||||||
2025-11-05 | NVCT | Nuvectis Pharma, Inc. | Bentsur Ron | COB, CEO, 10% | P - Purchase | $5.72 | +5,000 | 3,525,924 | 0% | +$28,600 | ||||||
2025-11-05 | NVCT | Nuvectis Pharma, Inc. | Sanchez Juan | Dir | P - Purchase | $5.79 | +13,000 | 78,565 | +20% | +$75,270 | ||||||
2025-11-05 | NVCT | Nuvectis Pharma, Inc. | Kaplan Matthew L. | Dir | P - Purchase | $5.84 | +11,000 | 124,760 | +10% | +$64,240 | ||||||
2025-11-05 | RLMD | Relmada Therapeutics, Inc. | Shenouda Maged | CFO | P - Purchase | $2.20 | +500,000 | 788,335 | +173% | +$1,100,000 | ||||||
2025-11-05 | RLMD | Relmada Therapeutics, Inc. | Ence Chuck | CAO, COO | P - Purchase | $2.20 | +136,000 | 403,931 | +51% | +$299,200 | ||||||
2025-11-05 | RLMD | Relmada Therapeutics, Inc. | Traversa Sergio | CEO | P - Purchase | $2.20 | +272,500 | 1,272,500 | +27% | +$599,500 | ||||||
2025-11-05 | RLMD | Relmada Therapeutics, Inc. | Kelly Paul Edward | COO | P - Purchase | $2.20 | +90,000 | 502,295 | +22% | +$198,000 | ||||||
2025-11-03 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO | S - Sale | $23.33 | -45,000 | 701,907 | -6% | -$1,049,778 | ||||||
| D | 2025-11-03 | CORT | Corcept Therapeutics Inc | Lyon Joseph Douglas | See Remarks | S - Sale+OE | $73.65 | -5,000 | 10,277 | -33% | -$368,245 | |||||
| M | 2025-11-03 | CORT | Corcept Therapeutics Inc | Belanoff Joseph K | CEO | S - Sale | $74.58 | -40,000 | 2,741,370 | -1% | -$2,983,119 | |||||
| D | 2025-11-03 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $73.99 | -20,000 | 117,621 | -15% | -$1,479,816 | |||||
| DM | 2025-11-03 | AXSM | Axsome Therapeutics, Inc. | Tabuteau Herriot | CEO, 10% | S - Sale+OE | $133.07 | -163,939 | 7,351,729 | -2% | -$21,815,669 | |||||
| M | 2025-11-03 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale | $24.12 | -6,486 | 98,325 | -6% | -$156,449 | |||||
2025-11-03 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale | $25.27 | -10,000 | 89,744 | -10% | -$252,669 | ||||||
2025-11-03 | ARQT | Arcutis Biotherapeutics, Inc. | Vairavan Latha | SVP CFO | S - Sale | $24.72 | -88 | 64,927 | 0% | -$2,175 | ||||||
2025-11-03 | ARQT | Arcutis Biotherapeutics, Inc. | Watanabe Todd | See Remarks | S - Sale | $24.72 | -11,547 | 1,028,027 | -1% | -$285,399 | ||||||
2025-11-03 | ARQT | Arcutis Biotherapeutics, Inc. | Matsuda Masaru | See Remarks | S - Sale | $24.72 | -7,208 | 154,026 | -4% | -$178,156 | ||||||
| D | 2025-11-04 | TERN | Terns Pharmaceuticals, Inc. | Quigley Jill M. | Dir | S - Sale+OE | $18.00 | -24,520 | 0 | -100% | -$441,360 | |||||
| D | 2025-11-05 | BGMS | Bio Green Med Solution, Inc. | Yap Kim Choy | 10% | S - Sale+OE | $1.70 | -28,540 | 467,535 | -6% | -$48,518 | |||||
2025-11-03 | LGND | Ligand Pharmaceuticals Inc | Kozarich John W | Dir | S - Sale | $191.05 | -467 | 44,588 | -1% | -$89,219 | ||||||
| D | 2025-11-03 | CRNX | Crinetics Pharmaceuticals, Inc. | Pizzuti Dana | Chief Med, Dev Officer | S - Sale+OE | $42.66 | -5,000 | 66,270 | -7% | -$213,312 | |||||
| D | 2025-11-04 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $436.09 | -21,000 | 8,118 | -72% | -$9,157,821 | |||||
2025-11-03 | PHAT | Phathom Pharmaceuticals, Inc. | Breedlove Robert Charles | Principal Accounting Officer | S - Sale | $13.51 | -524 | 54,352 | -1% | -$7,079 | ||||||
2025-11-03 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale | $25.72 | -5,931 | 7,195 | -45% | -$152,566 | ||||||
2025-11-03 | AMPH | Amphastar Pharmaceuticals, Inc. | Petersen Floyd F. | Dir | S - Sale | $25.27 | -500 | 75,531 | -1% | -$12,633 | ||||||
| D | 2025-11-03 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale+OE | $183.78 | -27,130 | 54,902 | -33% | -$4,985,911 | |||||
| DM | 2025-11-03 | GALT | Galectin Therapeutics Inc | Lewis Joel | Pres, CEO | S - Sale+OE | $6.07 | -15,720 | 834,592 | -2% | -$95,342 | |||||
| DM | 2025-11-03 | GALT | Galectin Therapeutics Inc | Callicutt Jack W | CFO | S - Sale+OE | $6.06 | -32,439 | 15,228 | -68% | -$196,676 | |||||
2025-11-04 | FOLD | Amicus Therapeutics, Inc. | Clark David Michael | Chief People Officer | S - Sale | $9.51 | -25,643 | 322,618 | -7% | -$243,860 | ||||||
2025-11-04 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $910.72 | -526 | 93,931,452 | 0% | -$479,038 | ||||||
| D | 2025-11-04 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $4.40 | -3,102 | 0 | -100% | -$13,634 | |||||
2025-11-03 | MTSR | Metsera, Inc. | Fmr LLC | See Remark 1, 10% | S - Sale | $61.23 | -193 | 3,094,182 | 0% | -$11,817 | ||||||
| D | 2025-11-04 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $59.55 | -2,295 | 140,610 | -2% | -$136,667 | |||||
| D | 2025-10-31 | KNSA | Kiniksa Pharmaceuticals International, Plc | Paolini John F. | CHIEF MEDICAL OFFICER | S - Sale+OE | $37.14 | -82,542 | 61,324 | -57% | -$3,065,610 | |||||
| DM | 2025-10-31 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $444.32 | -8,000 | 644,489 | -1% | -$3,554,592 | |||||
| D | 2025-11-03 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $429.25 | -22,500 | 2,648 | -89% | -$9,658,073 | |||||
| D | 2025-11-03 | ZLAB | Zai Lab Ltd | Chen Yajing | CFO | S - Sale+OE | $26.83 | -240 | 17,444 | -1% | -$6,439 | |||||
| D | 2025-10-31 | TVTX | Travere Therapeutics, Inc. | Coughlin Timothy | Dir | S - Sale+OE | $35.03 | -18,000 | 55,500 | -24% | -$630,601 | |||||
2025-10-31 | TVTX | Travere Therapeutics, Inc. | Heerma Peter | Chief Commercial Officer | S - Sale | $35.00 | -5,591 | 117,993 | -5% | -$195,685 | ||||||
2025-11-03 | MRK | Merck & Co., Inc. | Williams David Michael | EVP,Chief Info, Digital Office | S - Sale | $83.59 | -8,614 | 24,578 | -26% | -$720,040 | ||||||
2025-11-03 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $888.83 | -300,000 | 93,931,978 | 0% | -$266,648,921 | ||||||
2025-10-31 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $9.26 | +2,300 | 5,572,902 | 0% | +$21,298 | ||||||
| M | 2025-10-30 | IONS | Ionis Pharmaceuticals Inc | Wender Joseph H | Dir | S - Sale | $74.02 | -28,000 | 64,035 | -30% | -$2,072,578 | |||||
| D | 2025-10-31 | IONS | Ionis Pharmaceuticals Inc | Loscalzo Joseph | Dir | S - Sale+OE | $75.10 | -16,000 | 36,330 | -31% | -$1,201,669 | |||||
| DM | 2025-10-31 | IONS | Ionis Pharmaceuticals Inc | Geary Richard S | EVP, Chief Development Officer | S - Sale+OE | $75.11 | -90,929 | 59,657 | -60% | -$6,829,431 | |||||
2025-11-03 | NRIX | Nurix Therapeutics, Inc. | Van Houte Hans | CFO | S - Sale | $12.56 | -6,284 | 37,592 | -14% | -$78,931 | ||||||
| M | 2025-10-30 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $1.33 | -189,356 | 3,943,359 | -5% | -$251,349 | |||||
| M | 2025-10-30 | HOWL | Werewolf Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale | $1.33 | -295,043 | 6,147,610 | -5% | -$391,636 | |||||
| M | 2025-10-30 | HOWL | Werewolf Therapeutics, Inc. | Gadicke Ansbert | 10% | S - Sale | $1.33 | -295,043 | 6,147,610 | -5% | -$391,636 | |||||
2025-10-30 | BGMS | Bio Green Med Solution, Inc. | Yap Kim Choy | 10% | S - Sale | $1.81 | -112,260 | 28,500 | -80% | -$202,854 | ||||||
2025-10-30 | BGMS | Bio Green Med Solution, Inc. | Kua Khai Loon | 10% | S - Sale | $1.80 | -242,477 | 0 | -100% | -$436,459 | ||||||
2025-10-30 | BGMS | Bio Green Med Solution, Inc. | Ong Yee Lung | 10% | S - Sale | $1.80 | -248,814 | 0 | -100% | -$447,865 | ||||||
| M | 2025-05-14 | ORGO | Organogenesis Holdings Inc. | Nussdorf Glenn H | Dir, 10% | P - Purchase | $3.06 | +358,495 | 12,248,560 | +3% | +$1,096,039 | |||||
| M | 2025-06-09 | ORGO | Organogenesis Holdings Inc. | Nussdorf Glenn H | Dir, 10% | S - Sale | $3.55 | -22,776 | 12,248,560 | 0% | -$80,803 | |||||
2025-10-30 | RCUS | Arcus Biosciences, Inc. | Jaen Juan C. | Pres | S - Sale | $20.32 | -4,314 | 1,454,280 | 0% | -$87,650 | ||||||
| D | 2025-11-03 | ALKS | Alkermes Plc. | Hopkinson Craig C. | EVP R, D, Chief Medical Office | S - Sale+OE | $30.38 | -9,000 | 69,740 | -11% | -$273,442 | |||||
| D | 2025-10-30 | RYTM | Rhythm Pharmaceuticals, Inc. | Shulman Joseph | Chief Technical Officer | S - Sale+OE | $115.24 | -9,748 | 8,509 | -53% | -$1,123,398 | |||||
| D | 2025-10-30 | AGIO | Agios Pharmaceuticals, Inc. | Gheuens Sarah | Chief Medical Officer | S - Sale+OE | $43.81 | -200 | 61,727 | 0% | -$8,762 | |||||
2025-10-31 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $863.36 | -301,342 | 94,231,978 | 0% | -$260,165,031 | ||||||
2025-10-29 | BGMS | Bio Green Med Solution, Inc. | Yap Kim Choy | 10% | S - Sale | $1.83 | -110,749 | 140,760 | -44% | -$203,114 | ||||||
| D | 2025-10-30 | PTCT | Ptc Therapeutics, Inc. | Reeve Emma | Dir | S - Sale+OE | $69.50 | -15,666 | 6,666 | -70% | -$1,088,787 | |||||
2025-10-31 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.42 | +150,000 | 248,082,576 | 0% | +$213,435 | ||||||
| DM | 2025-10-29 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $442.37 | -8,000 | 644,489 | -1% | -$3,538,949 | |||||
2025-10-29 | BBIO | Bridgebio Pharma, Inc. | McCormick Frank | Dir | S - Sale | $66.58 | -198,359 | 763,254 | -21% | -$13,206,528 | ||||||
| D | 2025-10-30 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $102.92 | -4,000 | 48,034 | -8% | -$411,661 | |||||
| D | 2025-10-30 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | GC | S - Sale+OE | $103.16 | -21,800 | 49,086 | -31% | -$2,248,943 | |||||
2025-10-30 | ANNX | Annexon, Inc. | Carson William H. | Dir | P - Purchase | $3.17 | +4,115 | 46,175 | +10% | +$13,045 | ||||||
| D | 2025-10-29 | REGN | Regeneron Pharmaceuticals, Inc. | Poon Christine A | Dir | S - Sale+OE | $654.27 | -6,500 | 5,064 | -56% | -$4,252,745 | |||||
2025-10-29 | SYBX | Synlogic, Inc. | Dooley Mary Beth | See Remarks below | S - Sale | $1.81 | -157 | 12,744 | -1% | -$284 | ||||||
| D | 2025-10-28 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Officer | S - Sale+OE | $30.06 | -16,665 | 82,139 | -17% | -$500,987 | |||||
2025-10-28 | ARQT | Arcutis Biotherapeutics, Inc. | Watanabe Todd | See Remarks | S - Sale | $25.03 | -40,000 | 1,039,574 | -4% | -$1,001,032 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |